Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treatment with Tibsovo & Voranigo

At ASCO 2025, Servier presented data in the IDH-mutated cancer space.

Onsite at McCormick Place in Chicago, pharmaphorum web editor Nicole Raleigh spoke with Becky Martin, chief US medical at Servier about the key data from the company’s Tibsovo and Voranigo programmes, as well as the implications for patients and the wider themes of the Congress this year.

Listen to this and other interviews from ASCO 2025 here.